Premium
Heterozygous Genetic Variations of FOXP3 in X p11.23 Elevate Breast Cancer Risk in Chinese Population via Skewed X ‐Chromosome Inactivation
Author(s) -
Zheng Jian,
Deng Jieqiong,
Jiang Lan,
Yang Lei,
You Yonghe,
Hu Min,
Li Na,
Wu Hongchun,
Li Wei,
Li Hongbin,
Lu Jiachun,
Zhou Yifeng
Publication year - 2013
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.22284
Subject(s) - foxp3 , biology , allele , breast cancer , genotype , cancer research , population , gene , microbiology and biotechnology , immunology , genetics , cancer , immune system , medicine , environmental health
FOXP3 (forkhead box P 3: also known as IPEX , XPID ) is not only a hallmark of immunosuppressive regulatory T cells ( T regs), but also an X ‐linked breast cancer suppressor gene expressed in tumor cells. A two‐stage investigation was conducted in individuals from northern, southern and eastern C hina. Individuals carrying a FOXP3 rs2294021 CT genotype showed about 1.5‐fold increased risk of breast cancer compared with TT carriers. In a related biochemical assay, the rs2294021 C allele was found to significantly enhance transcription activity, leading to higher m RNA levels of FOXP3 compared with T allele. Moreover, the number of T regs and its corresponding interleukin‐10 ( IL ‐10) secretion were elevated whereas the proliferation of antitumor T cells was decreased in the C ‐allele carriers. The breast cancer oncogenes H er‐2/ E rb B 2 and S kp2 were also found to be significantly inhibited in C ‐allele carriers. Moreover, skewed X ‐chromosome inactivation ( SXCI ) analysis showed that rs2294021 CT carriers with SXCI showed higher risk than the homozygous carriers and CT carriers without SXCI , suggesting a possible interaction between the rs2294021 CT genotype and SXCI . Taken together, these findings indicate that the rs2294021 CT genotype may increase an individual's susceptibility to breast cancer by breaking the balance between T reg‐mediated immune tolerance and FOXP3 ‐controlled tumor‐suppressive effect.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom